Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Review, H2 2016 - Research and Markets
Thursday, 25 August 2016 06:06
Aug. 25, 2016 15:38 UTC

Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Review, H2 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016" drug pipelines to their offering.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Cognitive Impairment Associated With Schizophrenia Overview
  3. Therapeutics Development
  4. Pipeline Products for Cognitive Impairment Associated With Schizophrenia - Overview
  5. Pipeline Products for Cognitive Impairment Associated With Schizophrenia - Comparative Analysis
  6. Cognitive Impairment Associated With Schizophrenia - Therapeutics under Development by Companies
  7. Cognitive Impairment Associated With Schizophrenia - Therapeutics under Investigation by Universities/Institutes
  8. Cognitive Impairment Associated With Schizophrenia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cognitive Impairment Associated With Schizophrenia - Products under Development by Companies
  13. Cognitive Impairment Associated With Schizophrenia - Products under Investigation by Universities/Institutes
  14. Cognitive Impairment Associated With Schizophrenia - Companies Involved in Therapeutics Development
  • AbbVie Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Coronis Partners Ltd.
  • Eli Lilly and Company
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Iproteos S.L.

For more information about this drug pipelines visit http://www.researchandmarkets.com/research/jf4fpc/cognitive

Related Topics: Central Nervous System Drugs, Mental Disorders Drugs, Schizophrenia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter